8-K: Helius Medical Technologies Faces Nasdaq Delisting Threat Due to Stockholders' Equity Deficiency, Granted Extension to Regain Compliance

Helius Medical Technologies receives notice from Nasdaq regarding non-compliance with minimum stockholders' equity requirement and is granted an extension until June 30, 2025, to regain compliance.

Summary

• Helius Medical Technologies received a notice from Nasdaq on March 31, 2025, stating that it no longer complies with the minimum stockholders' equity requirement for continued listing.
• The company's stockholders' equity, as reported in its Annual Report on Form 10-K for the year ended December 31, 2024, has fallen below $2.5 million.
• The company also does not meet the alternative compliance standards.
• Previously, Helius received notice regarding non-compliance with the minimum bid price requirement.
• Nasdaq granted the company an extension until June 30, 2025, to regain compliance with both the minimum bid price and stockholders' equity requirements.
• The notices have no immediate impact on the listing of the company's common stock, which will continue to trade on Nasdaq under the symbol HSDT.
• The company will seek to regain compliance within the extension period.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and non-compliance with Nasdaq requirements, although the extension provides a chance for recovery.

Positives

• Nasdaq has granted Helius Medical Technologies an extension until June 30, 2025, to regain compliance with listing requirements.
• The company's common stock will continue to trade on Nasdaq under the symbol HSDT during the extension period, avoiding immediate delisting.

Negatives

• Helius Medical Technologies is not in compliance with Nasdaq's minimum stockholders' equity requirement, as its equity has fallen below $2.5 million.
• The company previously received notice regarding non-compliance with the minimum bid price requirement and was initially deemed ineligible for an additional extension.

Risks

• Failure to regain compliance with Nasdaq's minimum stockholders' equity and minimum bid price requirements by June 30, 2025, could result in delisting from The Nasdaq Stock Market LLC.
• Continued non-compliance could negatively impact investor confidence and the company's ability to raise capital.

Future Outlook

The company will seek to regain compliance with the Minimum Bid Price Requirement and the Stockholders Equity Requirement within the extension period ending June 30, 2025.

Industry Context

Many small-cap companies face challenges in maintaining Nasdaq listing compliance, particularly those in the biotechnology and medical technology sectors that require significant capital investment and may not yet be profitable. This situation is not uncommon, and companies often explore various strategies, including reverse stock splits, capital raises, or cost-cutting measures, to regain compliance.

Comparison to Industry Standards

• Many companies in the biotech sector, especially those in early stages, struggle with maintaining minimum equity requirements.
• For example, companies like Diffusion Pharmaceuticals and Athersys have faced similar challenges with Nasdaq compliance, often resorting to reverse stock splits or capital raises.
• Compared to industry peers, Helius's situation is not unique, but the outcome will depend on their ability to improve their financial position and market capitalization within the given timeframe.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value if the company fails to regain compliance.
• Employees may experience uncertainty due to the company's financial challenges and potential restructuring.
• The company's ability to secure future funding and partnerships could be affected by its Nasdaq listing status.

Next Steps

• Helius Medical Technologies will seek to regain compliance with the Minimum Bid Price Requirement and the Stockholders Equity Requirement.
• The company must meet the requirements by June 30, 2025, to avoid delisting.

Key Dates

Keywords

Nasdaq, delisting, stockholders' equity, minimum bid price, compliance, Helius Medical Technologies, HSDT